RALOXIFENE HCL AND PLACEBO IN PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSALS

雷洛昔芬盐酸盐和安慰剂预防绝经后骨质疏松症

• 批准号: 6291203
• 负责人: C. CONRAD JOHNSTON
• 金额: $ 0.04万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6291203
• 关键词: chemoprevention; clinical research; drug screening /evaluation; estrogen inhibitor; female; human subject; human therapy evaluation; osteoporosis; placebos; postmenopause; skeletal disorder chemotherapy; women's health

A multi-center, double-blind, placebo controlled study studying over 500 subjects at 8 study sites. Subjects will be randomly assigned to 4 parallel therapy groups. The objectives of this phase III trial are to establish the effect of long-term Raloxifene therapy, compared with placebo in healthy subjects.

一项多中心、双盲、安慰剂对照研究，研究了 8 个研究中心的 500 多名受试者。 受试者将被随机分配到 4 个平行治疗组。 这项 III 期试验的目的是确定雷洛昔芬与安慰剂在健康受试者中的长期治疗效果。